Stockholm-based Tandem Health, which makes an AI copilot that generates medical notes during consultations, raised a $100M Series B led by Scaleup Europe Fund
Context & Ripple Effects
Tandem Health's $100M Series B follows its $50M Series A for an AI medical copilot in 2025, marking a rapid escalation in funding behind clinician-facing documentation software. Syndicated coverage frames the round as backing a broader AI-native clinic operating system rather than a standalone note-taking tool.
The company enters a Nordic field that already includes Teton.ai's nurse-workflow companion and Corti's hospital transcription and paperwork copilot, making workflow breadth a more important competitive distinction than transcription alone.
First-order effects
- Tandem Health gains $100M in financing to develop its clinician copilot and the broader clinic operating-system product described in coverage of the round.
- Scaleup Europe Fund becomes the lead investor in Tandem Health's Series B, concentrating the company's next expansion phase around a larger institutional backer.
Second-order effects
- Teton.ai and Corti face a better-capitalized rival when selling AI workflow tools to healthcare providers, increasing pressure to distinguish their nursing- and call-focused products.
- Healthcare buyers evaluating documentation automation may encounter Tandem as a wider clinic-software vendor, not only as a consultation-note tool.
Third-order effects
- If companies such as Tandem successfully extend from note generation into clinic operations, healthcare AI competition will shift from point copilots toward integrated workflow platforms.
- The funding step adds to a pattern of larger rounds for AI products aimed at administrative clinical work, where product scope and provider adoption become linked.
The trend: Healthcare AI is moving from narrowly defined documentation copilots toward AI-native systems that seek to organize multiple clinical workflows.